SNCA and clostridium difficile infection: IPS was significantly higher in the low CDI group receiving CTLA4 + /PD1 − and CTLA4 + /PD1 + treatments (Fig. 11B), suggesting that patients with a low CDI respond better to anti-CTLA4 or combined anti-CTLA4 and anti-PD1 therapy.